Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate.
Open Access
- 1 January 1996
- journal article
- clinical trial
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 97 (1), 73-80
- https://doi.org/10.1172/jci118409
Abstract
Methotrexate (MTX) is one of the most widely used drugs for the treatment of childhood acute lymphoblastic leukemia (ALL) and is commonly given in high doses. However, the rationale for high-dose MTX (HDMTX) has been challenged recently. To determine whether higher MTX polyglutamate (MTXPG) concentrations in ALL blasts translate into greater antileukemic effects, 150 children with newly diagnosed ALL were randomized to initial treatment with either HDMTX (1,000 mg/m2 intravenously over 24 h) or lower-dose MTX (30 mg/m2 by mouth every 6 h x 6). ALL blasts accumulated higher concentrations of MTXPG and long-chain MTXPG (MTXPGLC) after HDMTX (P < 0.00001). Of 101 patients evaluable for peripheral blast cytoreduction, MTXPG concentrations were higher in patients whose blast count decreased within 24 h (P = 0.005) and in those who had no detectable circulating blasts within 4 days (P = 0.004). The extent of inhibition of de novo purine synthesis in ALL blasts was significantly related to the blast concentration of MTXPGLC (IC95% = 483 pmol/10(9) blasts). The percentage of patients with 44-h MTXPGLC exceeding the IC95% was greater after HDMTX (81%) than LDMTX (46%, P < 0.0001). These data indicate that higher blast concentrations of MTXPG are associated with greater antileukemic effects, establishing a strong rationale for HD-MTX in the treatment of childhood ALL.Keywords
This publication has 39 references indexed in Scilit:
- Childhood LeukemiasNew England Journal of Medicine, 1995
- Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia.JCI Insight, 1994
- Biology and treatment of acute lymphoblastic leukemiaThe Journal of Pediatrics, 1994
- High-Dose Methotrexate: Is it Warranted?Pediatric Hematology and Oncology, 1994
- Results of the LMT81 protocol, a modified LSA2L2 protocol with high dose methotrexate, on 84 children with non‐B‐cell (lymphoblastic) lymphomaMedical and Pediatric Oncology, 1992
- Methotrexate bioavailability after oral and intramuscular administration in childrenThe Journal of Pediatrics, 1987
- Clinical Pharmacodynamics of High-Dose Methotrexate in Acute Lymphocytic LeukemiaNew England Journal of Medicine, 1986
- Polyglutamation of methotrexate. Is methotrexate a prodrug?JCI Insight, 1985
- Urate-oxidase prophylaxis of uric acid-induced renal damage in childhood leukemiaThe Journal of Pediatrics, 1982
- THE CHARACTERISTICS OF THE MEMBRANE TRANSPORT OF AMETHOPTERIN AND THE NATURALLY OCCURRING FOLATESAnnals of the New York Academy of Sciences, 1971